Outlook Therapeutics (OTLK) Notes Payables (2015 - 2020)
Outlook Therapeutics (OTLK) posted quarterly Notes Payables of $3.6 million for Q3 2020, little changed year-over-year from $3.6 million in Q4 2019, and little changed quarter-over-quarter from $3.6 million in Q2 2020.
Outlook Therapeutics (OTLK) Notes Payables (2015 - 2020) Analysis & Trends
Outlook Therapeutics (OTLK) has reported Notes Payables for 6 consecutive years, with $3.6 million the latest figure, recorded in Q3 2020.
- In Q3 2020, Notes Payables changed 0.0% year-over-year to $3.6 million; the TTM figure through Sep 2020 stood at $3.6 million (changed 0.0% YoY), while the FY2020 annual figure was $3.6 million, changed 0.0% from the prior year.
- Notes Payables held at $3.6 million in Q3 2020 per OTLK's latest filing, from $3.6 million in the prior quarter.
- Across five years, Notes Payables topped out at $9.7 million in Q1 2016 and bottomed at $3.6 million in Q1 2019.
- Historically, Notes Payables has averaged $4.5 million across 5 years, with a median of $4.6 million in 2016.
- Annual changes were most pronounced in 2016 — Notes Payables tumbled 67.55% — and 2017, when it changed 0.0%.
- Outlook Therapeutics' Notes Payables stood at $4.6 million in 2016, then changed by 0.0% to $4.6 million in 2017, then changed by 0.0% to $4.6 million in 2018, then declined by 21.68% to $3.6 million in 2019, then changed by 0.0% to $3.6 million in 2020.
- Business Quant data shows OTLK's Notes Payables at $3.6 million in Q3 2020, $3.6 million in Q2 2020, and $3.6 million in Q1 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.40 Bn | 131.54 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.13 Bn | 78.13 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.58 Bn | 60.40 Bn | 1.37 Bn |
| 4 | Moderna | 58.23 Bn | 53.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.18 Bn | 37.08 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.61 Bn | 28.30 Bn | 992.69 Mn |
| 7 | BioNTech SE | 27.97 Bn | 9.58 Bn | 668.28 Mn |
| 8 | Insmed | 27.55 Bn | 26.39 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.31 Bn | 26.47 Bn | - |
| 10 | Outlook Therapeutics | 88.91 Mn | 77.67 Mn | -8,265.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2020 | 3.61 Mn |
| Jun 30, 2020 | 3.61 Mn |
| Mar 31, 2020 | 3.61 Mn |
| Dec 31, 2019 | 3.61 Mn |
| Sep 30, 2019 | 3.61 Mn |
| Jun 30, 2019 | 3.61 Mn |
| Mar 31, 2019 | 3.61 Mn |
| Dec 31, 2018 | 4.61 Mn |
| Sep 30, 2018 | 4.61 Mn |
| Jun 30, 2018 | 4.61 Mn |
| Mar 31, 2018 | 4.61 Mn |
| Dec 31, 2017 | 4.61 Mn |
| Sep 30, 2017 | 4.61 Mn |
| Jun 30, 2017 | 4.61 Mn |
| Mar 31, 2017 | 4.61 Mn |
| Dec 31, 2016 | 4.61 Mn |
| Sep 30, 2016 | 4.61 Mn |
| Jun 30, 2016 | 4.61 Mn |
| Mar 31, 2016 | 9.65 Mn |
| Sep 30, 2015 | 14.21 Mn |